MX2019015733A - Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva. - Google Patents

Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.

Info

Publication number
MX2019015733A
MX2019015733A MX2019015733A MX2019015733A MX2019015733A MX 2019015733 A MX2019015733 A MX 2019015733A MX 2019015733 A MX2019015733 A MX 2019015733A MX 2019015733 A MX2019015733 A MX 2019015733A MX 2019015733 A MX2019015733 A MX 2019015733A
Authority
MX
Mexico
Prior art keywords
saliva
melatonin
renders
soluble
acidifying agent
Prior art date
Application number
MX2019015733A
Other languages
English (en)
Inventor
M Shah Syed
Hassan Daniel
Hassan Fred
Corsino Patrick
Original Assignee
Physicians Seal Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physicians Seal Llc filed Critical Physicians Seal Llc
Publication of MX2019015733A publication Critical patent/MX2019015733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición que incluye una forma de dosificación farmacéutica configurada para desintegrarse en saliva y mantener un pH de 4 o menos dentro de la saliva durante el tiempo en que la forma de dosificación se disuelva en la misma. La forma de dosificación incluye una cantidad terapéuticamente eficaz de melatonina en una matriz portadora, un desintegrante y una cantidad suficiente de ácido para conferirle pH a la saliva. La cantidad de desintegrante es suficiente para hacer que la forma de dosificación se desintegre completamente en la saliva dentro de los diez minutos posteriores al contacto con la saliva.
MX2019015733A 2017-06-20 2018-06-15 Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva. MX2019015733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522473P 2017-06-20 2017-06-20
PCT/US2018/037698 WO2018236678A1 (en) 2017-06-20 2018-06-15 ORAL DISSOLUTION MELATONIN FORMULATION WITH ACIDIFYING AGENT THAT MAKES MELATONIN SOLUBLE IN SALIVA

Publications (1)

Publication Number Publication Date
MX2019015733A true MX2019015733A (es) 2020-02-20

Family

ID=64656010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015733A MX2019015733A (es) 2017-06-20 2018-06-15 Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.

Country Status (13)

Country Link
US (4) US10500280B2 (es)
EP (1) EP3641759B1 (es)
JP (1) JP7297685B2 (es)
KR (1) KR20200018652A (es)
CN (1) CN110913853A (es)
AU (1) AU2018289284A1 (es)
BR (2) BR112019027286B1 (es)
CA (1) CA3067822C (es)
ES (1) ES2979335T3 (es)
MX (1) MX2019015733A (es)
RU (1) RU2020101742A (es)
SG (1) SG11201912172YA (es)
WO (1) WO2018236678A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019027286B1 (pt) 2017-06-20 2022-02-22 Société Des Produits Nestlé S.A Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
WO2022170442A1 (en) * 2021-02-12 2022-08-18 Intelgenx Corp. Novel tryptamine oral film formulation
US20240269079A1 (en) * 2021-06-09 2024-08-15 Agb-Pharma Ab Melatonin formulation in solid dosage form

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
EP1490031A1 (en) 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US20050164987A1 (en) 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
KR20130116378A (ko) 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20080102133A1 (en) 2004-10-05 2008-05-01 Antje Brueck-Scheffler Oral Pharmaceutical Preparation for Proton Pump Antagonists
KR20070111497A (ko) * 2005-02-10 2007-11-21 오렉쏘 에이비 약의 경점막 투여에 유용한 새로운 약학 조성물
JP2009527504A (ja) 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
ES2575549T3 (es) 2007-04-11 2016-06-29 John A. Mccarty Comprimido de melatonina y métodos de preparación y uso
US20080260823A1 (en) 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
CA2685593A1 (en) 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
KR100905027B1 (ko) * 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
EP2265259A1 (en) * 2008-04-25 2010-12-29 Cadila Healthcare Limited Rapidly disintegrating oral compositions of tramadol
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US20120213855A1 (en) 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US20130052234A1 (en) 2011-08-25 2013-02-28 Purebrands LLC Edible strips
ES2457718B1 (es) 2012-09-24 2015-04-16 Universidad De Granada Composición farmacéutica bucodispersable de melatonina
US20140303227A1 (en) 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
ES2914899T3 (es) * 2015-03-02 2022-06-17 Medlab Clinical U S Inc Sistemas de suministro transmucosa y transdérmico
BR112019027286B1 (pt) * 2017-06-20 2022-02-22 Société Des Produits Nestlé S.A Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva

Also Published As

Publication number Publication date
RU2020101742A (ru) 2021-07-20
BR112019027286B1 (pt) 2022-02-22
JP2020524162A (ja) 2020-08-13
BR112019027286A2 (pt) 2020-07-21
US20180360967A1 (en) 2018-12-20
US20200069803A1 (en) 2020-03-05
US10500280B2 (en) 2019-12-10
SG11201912172YA (en) 2020-01-30
CA3067822A1 (en) 2018-12-27
JP7297685B2 (ja) 2023-06-26
EP3641759A4 (en) 2021-03-24
WO2018236678A1 (en) 2018-12-27
AU2018289284A1 (en) 2020-01-16
ES2979335T3 (es) 2024-09-25
US11224658B2 (en) 2022-01-18
BR122021012549B1 (pt) 2022-02-22
KR20200018652A (ko) 2020-02-19
CN110913853A (zh) 2020-03-24
US11224657B2 (en) 2022-01-18
EP3641759A1 (en) 2020-04-29
US20200268887A1 (en) 2020-08-27
BR122021012549B8 (pt) 2022-10-25
US20200268886A1 (en) 2020-08-27
EP3641759B1 (en) 2024-04-03
CA3067822C (en) 2022-08-30
US10960075B2 (en) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2019015733A (es) Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
MX2024010140A (es) Nuevos metodos.
MX2021002322A (es) Nuevos metodos.
MX2019004238A (es) Composiciones farmaceuticas liofilizadas para suministro vaginal.
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX365216B (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
PH12015502274B1 (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
EP4393548A3 (en) Formulations and treatments employing hydroxypyridonate actinide/lanthanide decorporation agents
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
MX2022015232A (es) Composicion farmaceutica acuosa de levilimab y su uso.
MX2021008303A (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
MX2018013569A (es) Composicion valeriana y metodos relacionados.
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
PL422140A1 (pl) Zastosowanie totarolu i kompozycja farmaceutyczna zawierająca totarol

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SOCIETE DES PRODUITS NESTLE S. A.